Treatment for Citrobacter Infections

Rationale for Meropenem Selection

The Infectious Diseases Society of America recommends meropenem as the first-line agent for treating Citrobacter infections, particularly when extended-spectrum beta-lactamase (ESBL) production or AmpC hyperproduction is suspected or confirmed, due to its effectiveness against gram-negative bacilli that may hyperproduce lactamases 1
Meropenem is preferred over third-generation cephalosporins, which can be ineffective due to AmpC derepression during treatment, leading to clinical failure 1

The recommended dosing regimen for standard Citrobacter infections is meropenem 1 gram IV every 8 hours, with a treatment duration of 5-7 days, individualized based on infection site, source control adequacy, and clinical response 2, 3
For severe infections or suspected high MIC (≥8 mg/L), meropenem 1-2 grams IV every 8 hours via extended infusion over 3 hours is recommended, as it optimizes pharmacodynamic targets by maximizing time above MIC 2, 3

The Infectious Diseases Society of America advises against using third-generation cephalosporins alone for Citrobacter infections, even if initial susceptibility testing suggests sensitivity, due to the risk of AmpC derepression during therapy 1
Source control is essential when applicable, as antimicrobial therapy alone is insufficient for abscesses, infected devices, or obstructed systems 4

For neonates and immunocompromised patients, meropenem remains the preferred agent, with dosing adjusted for age and renal function, and combination therapy may be warranted in severely ill patients 1, 5
For carbapenem-resistant Citrobacter, ceftazidime-avibactam or meropenem-vaborbactam may be used based on susceptibility testing, and combination therapy with polymyxins or tigecycline may be considered 3, 5